{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:45:23Z","timestamp":1771843523382,"version":"3.50.1"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Evocalcet is a novel calcimimetic agent with fewer gastrointestinal (GI) adverse effects compared to cinacalcet. Although it is thought that cinacalcet induces GI side effects through the direct stimulation of the calcium receptor (CaR) expressed in the GI tract, the differences in the direct stimulatory effects of these two drugs on the GI tract have not been reported. In this study, we analyzed the difference in the GI effects of these two calcimimetic agents using miniature pigs by detecting vagus nerve stimulation after oral administration of the agents. Although cinacalcet induced vomiting in miniature pigs, evocalcet never induced emetic symptoms. A significant increase in the vagus nerve action potentials was observed after the administration of cinacalcet. Although the increase of that after the administration of evocalcet was mild and not significant in comparison to that in the vehicle group, it was not significantly different from the vagus nerve action potentials after cinacalcet treatment.<\/jats:p>","DOI":"10.1371\/journal.pone.0245785","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T21:06:01Z","timestamp":1611349561000},"page":"e0245785","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs"],"prefix":"10.1371","volume":"16","author":[{"given":"Shin","family":"Tokunaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1167-6925","authenticated-orcid":true,"given":"Takehisa","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"pone.0245785.ref001","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"J Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0245785.ref002","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"F Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"pone.0245785.ref003","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"EF Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0245785.ref004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2215\/CJN.00870805","article-title":"Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate","volume":"1","author":"GM Chertow","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"pone.0245785.ref005","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"GM Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"pone.0245785.ref006","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/j.1523-1755.2005.00596.x","article-title":"Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism","volume":"68","author":"J Cunningham","year":"2005","journal-title":"Kidney Int"},{"key":"pone.0245785.ref007","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"P Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"pone.0245785.ref008","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Y Gincherman","year":"2010","journal-title":"Hemodial Int"},{"key":"pone.0245785.ref009","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"GA Block","year":"2004","journal-title":"N Engl J Med"},{"key":"pone.0245785.ref010","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.bmcl.2018.04.055","article-title":"Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism","volume":"28","author":"H Miyazaki","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"key":"pone.0245785.ref011","doi-asserted-by":"crossref","first-page":"e0195316","DOI":"10.1371\/journal.pone.0195316","article-title":"A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro","volume":"13","author":"T Kawata","year":"2018","journal-title":"PLoS One"},{"key":"pone.0245785.ref012","doi-asserted-by":"crossref","first-page":"e0232428","DOI":"10.1371\/journal.pone.0232428","article-title":"Evocalcet prevents ectopic calcification and parathyroid hyperplasia in rats with secondary hyperparathyroidism","volume":"15","author":"M Sakai","year":"2020","journal-title":"PLoS One"},{"key":"pone.0245785.ref013","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1254\/fpj.154.35","article-title":"Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA\u00ae)","volume":"154","author":"S Tokunaga","year":"2019","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"pone.0245785.ref014","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"M Fukagawa","year":"2018","journal-title":"Kidney Int"},{"key":"pone.0245785.ref015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/bdd.2510160502","article-title":"Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals","volume":"16","author":"TT Kararli","year":"1995","journal-title":"Biopharm Drug Dispos"},{"key":"pone.0245785.ref016","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1196\/annals.1334.015","article-title":"The miniature pig as an animal model in biomedical research","volume":"1049","author":"P Vodicka","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"pone.0245785.ref017","first-page":"951","article-title":"The piglet as a suitable animal model for studying the delayed phase of cisplatin-induced emesis","volume":"274","author":"S Milano","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0245785.ref018","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1254\/jjp.59.221","article-title":"Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs","volume":"59","author":"H Fukui","year":"1992","journal-title":"Jpn J Pharmacol"},{"key":"pone.0245785.ref019","first-page":"943","article-title":"Hypercalcemia in malignancy","volume":"42","author":"S Eto","year":"1994","journal-title":"Rinsho Byori"},{"key":"pone.0245785.ref020","first-page":"1029","article-title":"Hypercalcemic crisis and hypocalcemic tetany","volume":"58","author":"C Kasperk","year":"2017","journal-title":"Internist (Berl)"},{"key":"pone.0245785.ref021","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/1742-6723.13411","article-title":"Risk variables associated with abnormal calcium, magnesium and phosphate levels among emergency department patients","volume":"32","author":"DM Taylor","year":"2020","journal-title":"Emerg Med Australas"},{"key":"pone.0245785.ref022","doi-asserted-by":"crossref","first-page":"7617254","DOI":"10.1155\/2019\/7617254","article-title":"Symptomatic hypercalcemia in patients with primary hyperparathyroidism is associated with severity of disease, polypharmacy, and comorbidity","volume":"2019","author":"C Aresta","year":"2019","journal-title":"Int J Endocrinol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245785","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T21:06:20Z","timestamp":1611349580000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0245785"}},"subtitle":[],"editor":[{"given":"Olivier","family":"Barbier","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0245785","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,22]]}}}